Review
Oncology
Shinji Tsukamoto, Andreas F. Mavrogenis, Lucia Angelelli, Alberto Righi, Giuseppe Filardo, Akira Kido, Kanya Honoki, Yuu Tanaka, Yasuhito Tanaka, Costantino Errani
Summary: The 5-year disease-free survival rate for patients with localized extraskeletal osteosarcoma (ESOS) who underwent surgery combined with (neo)adjuvant chemotherapy was slightly higher than those who underwent surgery alone. Therefore, routine adjuvant chemotherapy for localized ESOS should be avoided.
Review
Oncology
Xiao Ma, Jin Fang, Lu Zhang, Yao Huang, Hui Shen, Xiaohua Ma, Shuixing Zhang, Bin Zhang
Summary: This study analyzed the treatment of locally advanced cervical cancer (LACC) and found that adjuvant chemotherapy (ACT) does not provide additional survival benefits. However, it is necessary to identify high-risk patients who may benefit from ACT in order to make better treatment decisions.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Xingfa Huo, Jinming Li, Fuxing Zhao, Dengfeng Ren, Raees Ahmad, Xinyue Yuan, Feng Du, Jiuda Zhao
Summary: The meta-analysis demonstrated that combined neoadjuvant and adjuvant chemotherapy with capecitabine significantly improved DFS and OS in early-stage TNBC patients, with tolerable adverse events. There were benefits in DFS for patients with the addition of capecitabine, adjuvant chemotherapy, and lymph node positivity.
Review
Surgery
Nguyen-Phong Vo, Hung Song Nguyen, El-Wui Loh, Ka-Wai Tam
Summary: Adjuvant therapy is significantly associated with decreased mortality risk in ampullary carcinoma patients, especially for high-risk patients and those with the pancreaticobiliary subtype. However, it does not improve overall survival in low-risk patients and those with the intestinal subtype. Additionally, adjuvant therapy shows good safety performance with no intervention-related mortality.
Review
Oncology
Ziwei Zhu, Yunyuan Xiao, Shengye Hu, Ziyuan Wang, Zaisheng Zhu
Summary: For patients with variant histology bladder cancers, neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) can improve overall survival (OS) and cancer-specific survival (CSS) compared with radical cystectomy alone. NAC benefits the sarcomatoid and neuroendocrine subgroups, while only the neuroendocrine subgroup shows improved CSS with AC.
FRONTIERS IN ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
Florian E. Buisman, Wills F. Filipe, Boris Galjart, Dirk J. Grunhagen, Marjolein Y. V. Homs, Adriaan Moelker, Cornelis Verhoef, Bas Groot Koerkamp
Summary: This meta-analysis demonstrates that adjuvant hepatic arterial infusion chemotherapy (HAIC) is a promising treatment for patients with resectable colorectal liver metastasis (CRLM), particularly when using floxuridine, a surgically placed catheter with a subcutaneous pump, and concomitant systemic chemotherapy.
Review
Oncology
Matteo Lambertini, Eva Blondeaux, Marco Bruzzone, Marta Perachino, Richard A. Anderson, Evandro de Azambuja, Philip D. Poorvu, Hee Jeong Kim, Cynthia Villarreal-Garza, Barbara Pistilli, Ines Vaz-Luis, Cristina Saura, Kathryn J. Ruddy, Maria Alice Franzoi, Chiara Sertoli, Marcello Ceppi, Hatem A. Azim, Frederic Amant, Isabelle Demeestere, Lucia Del Mastro, Ann H. Partridge, Olivia Pagani, Fedro A. Peccatori
Summary: This study found that breast cancer survivors are less likely to have a subsequent pregnancy compared to the general population, and they face higher risks during pregnancy, especially among those who have received chemotherapy. However, compared to breast cancer patients without subsequent pregnancy, those who become pregnant have better disease-free survival and overall survival rates.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Sang-Ho Jeong, Rock Bum Kim, Sung Eun Oh, Ji Yeong An, Kyung Won Seo, Jae-Seok Min
Summary: This study compared the efficacy of S-1 and CAPOX regimens in stage II or III gastric cancer patients. The results showed that there was no significant difference in five-year overall survival (OS) and disease-free survival (DFS) between the two regimens in all stages. This indicates that S-1 and CAPOX regimens have comparable efficacy in treating stage II or III gastric cancer patients.
Review
Oncology
Delia Morlino, Iolanda Cioffi, Maurizio Marra, Olivia Di Vincenzo, Luca Scalfi, Fabrizio Pasanisi
Summary: This systematic review explores the use of phase angle (PhA) in breast cancer (BC) patients and its relationship with nutritional status and survival. The findings indicate that PhA decreases after chemotherapy in BC patients, but tailored lifestyle interventions can prevent this decrease. High PhA values are associated with better nutritional status, but there is inconsistent data on survival. Further studies are needed to determine the clinical relevance of PhA in BC patients and its association with disease outcomes and survival.
Article
Oncology
Jaileene Perez-Morales, Kristy K. Broman, Deepti Bettampadi, Mary Katherine Haver, Jonathan S. Zager, Matthew B. Schabath
Summary: This systematic review aims to examine the timing and patterns of recurrence for patients with regionally metastatic melanoma based on nodal management and adjuvant therapy. The study found that adjuvant treatment improved recurrence-free survival (RFS), but did not alter the patterns of recurrence. Future studies should report the specific sites of disease recurrence based on adjuvant systemic treatment and surveillance practices to provide better advice to patients about their recurrence patterns and risks.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Jianbing Chen, Chengda Zhang, Yajuan Wu
Summary: Pooling data from real-world studies showed that adjuvant chemotherapy significantly improved overall survival but not disease-free survival in elderly colorectal cancer patients. Limited evidence suggests a restricted role of adjuvant chemotherapy in Asian patients, which needs further confirmation.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Oncology
Daniele Medeiros Torres, Rosalina Jorge Koifman, Sabrina da Silva Santos
Summary: This study assessed the impact of different types of physical exercises on fatigue during adjuvant treatment in women with breast cancer. The results showed that physical exercise was effective in reducing fatigue, with supervised combination of resistance training and aerobic training being the most effective.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Oncology
Nicholas A. Bosma, Alysha R. Keehn, Richard Lee-Ying, Safiya Karim, Anthony R. MacLean, Darren R. Brenner
Summary: Perioperative chemotherapy in patients with resected CRLM improved disease-free survival (DFS) but did not show a benefit in overall survival (OS). Further research is needed to determine the optimal regimen and sequencing of perioperative chemotherapy.
Review
Urology & Nephrology
Carlos Riveros, Emily Huang, Sanjana Ranganathan, Zachary Klaassen, Brian Rini, Christopher J. D. Wallis, Raj Satkunasivam
Summary: This study synthesized available data on the disease-free survival (DFS) benefit of adjuvant immune checkpoint inhibitors (ICIs) for renal cell carcinoma (RCC) patients and evaluated the overall safety profile of ICIs in this setting. The results showed that although pooled analyses did not demonstrate a significant overall DFS benefit, there was a significant benefit among patients with positive PD-L1 expression and sarcomatoid features. Therefore, ICIs may be a treatment option for adjuvant therapy in RCC.
Review
Oncology
E. Agostinetto, L. Vian, R. Caparica, M. Bruzzone, M. Ceppi, M. Lambertini, N. Ponde, E. de Azambuja
Summary: The addition of CDK4/6is to adjuvant ET for patients with HR+/HER2- early breast cancer showed a trend for improved invasive disease-free survival (IDFS) but did not significantly improve distant relapse-free survival. However, it increased the risk of toxicities and treatment discontinuation. Further follow-up of randomized controlled trials is needed to clarify the role of adjuvant CDK4/6is before considering changes in clinical practice.
